NKTR Stock Analysis: Buy, Sell, or Hold?
NKTR - Nektar Therapeutics
$73.20
-2.75 (-3.62%)
▼
5d:
-12.2%
30d:
-12.04%
90d:
+3.1%
WAIT
LOW Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Smart Money Distribution
NKTR is up 8.0% this week, but smart money is buying puts. Top strike: $85 2026-06-18 with 2,678 OI. Put ratio: 70% View Scanner →
Strength: 6.0/10
Get Alerted When NKTR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NKTR is down 12.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NKTR is down 12.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NKTR is currently trading at $73.20, which is considered slightly low relative to its 30-day fair value range of $77.78 to $90.53.
Technical Outlook: Technically, NKTR is in a strong uptrend. The price is currently testing key support at $73.50. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $153.25 (+101.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NKTR is in a strong uptrend. The price is currently testing key support at $73.50. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $153.25 (+101.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$77.78 -
$90.53
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 101.8% below Wall St target ($153.25)
- WARNING: Recommendation downgraded due to -12.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$77.78 -
$90.53
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$73.50
Resistance Level
$88.10
Current Trend
Strong Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.05
Wall Street Target
$153.25
(+101.8%)
Revenue Growth (YoY)
3.8%
Profit Margin
-284.2%
Share & Embed Analysis
Last updated: May 14, 2026 1:42 PM ET
Data refreshes hourly during market hours. Next update: 2:42 PM
Data refreshes hourly during market hours. Next update: 2:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NKTR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Jonathan Zalevsky
SELL
180 shares
2026-02-18
Howard W Robin
SELL
423 shares
2026-02-18
Jonathan Zalevsky
SELL
3867 shares
2026-01-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 57 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 59 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 64 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 55 HOLD |
